Отворите главни мени

Промене

39 бајтова додато ,  пре 5 месеци
м
Разне исправке
'''Farmakokinetika''', skraćeno ''PK'', (od [[Старогрчки језик|starogrčkog]] -{''pharmakon''}- "lek" i -{''kinetikos''}- "vezano za kretanje") je grana [[farmakologija|farmakologije]] koja se bavi izučavanjem promena supstanci doziranih u žive organizme. Reč farmakokinetika prvi put uveo je [[Friedrich Hartmut Dost]] 1953. godine u Nemačkoj i disciplinu definisao kao nauku kvantitativne analize odnosa između organizma i leka. Supstance od interesa su farmaceutski agensi, hormoni, nutrijenti, i toksini. Ona pokušava da otkrije sudbinu leka od momenta njegovog unosa do tačke u kojoj je kompletno eliminisan iz tela.
{{Кутијица за цитат
|цитат = '''Farmakokinetika''' se može jednostavno definisati kao to što telo radi leku, dok je '''farmakodinamika''' usredsređena na to što lek radi telu.<ref>{{Cite book | editor = Horning MG, Mitchell J | title = Drug metabolism and drug toxicity | publisher = Raven Press | location = New York |year=1984 |idisbn=ISBN 978-0-89004-997-6 | chapter = Pharmacokinetics: Basic Principles and Its Use as a Tool in Drug Metabolism | chapterurl = http://bts.ucsf.edu/benet_lab/index.php?page=benet | author = Benet LZ |pages=}}</ref>
|ширина = 40%
}}
[[Датотека:Gráfica Km.png|мини|250px250п|Grafikon koji demonstrira [[Михаелис-Ментенина кинетика|Mihaelis-Menteninov kinetčki]] model odnosa između enzima i supstrata]]
 
Farmakokinetika opisuje kako telo deluje na specifični lek nakon doziranja putem mehanizama apsorpcije i distribucije, kao i hemijske promene supstane u telu (e.g. posredstvom metaboličkih enzima kao što su [[enzim]]i [[citohrom P450]] ili [[glukuronoziltransferaza]]), i efekte i puteve izlučivanja metabolita leka.<ref>Pharmacokinetics. (2006). In ''Mosby's Dictionary of Medicine, Nursing, & Health Professions''. Philadelphia, PA: Elsevier Health Sciences. RetrievedПриступљено December 11, 2008, from http://www.credoreference.com/entry/6686418 </ref> Farmakokinetička svojstva leka mogu da budu uslovljena faktorima poput mesta administriranja i doze leka. Ti faktori mogu da utiču na brzinu apsorpcije.<ref>{{Cite book |author=Kathleen Knights; Bronwen Bryant |title=Pharmacology for Health Professionals |publisher=Elsevier |location=Amsterdam |year=2002 |idisbn=ISBN 978-0-7295-3664-6 |oclc= |doi= |accessdate=|pages=}}</ref> Farmakokinetika se često studira zajedno sa [[farmakodinamika|farmakodinamikom]].
 
== Vidi još ==
== Literatura ==
{{refbegin|2}}
* {{Cite book |ref= harv|editor = Horning MG, Mitchell J | title = Drug metabolism and drug toxicity | publisher = Raven Press | location = New York |year=1984 |idisbn=ISBN 978-0-89004-997-6 | chapter = Pharmacokinetics: Basic Principles and Its Use as a Tool in Drug Metabolism | chapterurl = http://bts.ucsf.edu/benet_lab/index.php?page=benet | author = Benet LZ }}
* {{Cite book |ref= harv|author=Kathleen Knights; Bronwen Bryant |title=Pharmacology for Health Professionals |publisher=Elsevier |location=Amsterdam |year=2002 |idisbn=ISBN 978-0-7295-3664-6 |oclc= |doi= |accessdate=}}
* Alberts et al., ''Introducción a la Biología Celular'', pág. 375-376, 2ª edición, Ed. Médica Panamericana
* Alberts et al., ''Biología Molecular de la célula'', pág. 595, 4ª edición, Ed. Omega
* Danielson P (2002). "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans". Curr Drug Metab 3 (6): 561-97. PMID 12369887.
* Davies K (1995). "Oxidative stress: the paradox of aerobic life". Biochem Soc Symp 61: 1-31. PMID 8660387.
* Devlin, T. M. 2004. ''Bioquímica'', 4ª edición. Reverté, Barcelona. ISBN {{page|year=|isbn=978-84-291-7208-9|pages=}}
* Galvão T, Mohn W, de Lorenzo V (2005). "Exploring the microbial biodegradation and biotransformation gene pool". Trends Biotechnol 23 (10): 497-506. PMID 16125262.
* Hsieh Y, Korfmacher WA "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism 7 (5): 479–89.(June 2006). PMID 16787157. Disponible en [http://www.bentham-direct.org/pages/content.php?CDM/2006/00000007/00000005/0004F.SGM.]{{Мртва веза|date=09. 2018. |bot=InternetArchiveBot |fix-attempted=yes }}
* Janssen D, Dinkla I, Poelarends G, Terpstra P (2005). "Bacterial degradation of xenobiotic compounds: evolution and distribution of novel enzyme activities". Environ Microbiol 7 (12): 1868-82. PMID 16309386.
* Kathleen Knights; Bronwen Bryant (2002). ''Pharmacology for Health Professionals''. Amsterdam: Elsevier. ISBN {{page|year=|isbn=978-0-7295-3664-6|pages=}}.
* King C, Rios G, Green M, Tephly T (2000). "UDP-glucuronosyltransferases". Curr Drug Metab 1 (2): 143-61. PMID 11465080.
* Malcolm Rowland, Thomas N. Tozer. "Farmacocinética clínica: Conceptos y Aplicaciones"
* Singh SS., ''Preclinical pharmacokinetics: an approach towards safer and efficacious drugs'', Curr Drug Metab. 2006 Feb;7(2):165-82.
* Testa B, Krämer S (2006). "The biochemistry of drug metabolism--an introduction: part 1. Principles and overview". Chem Biodivers 3 (10): 1053-101. PMID 17193224.
* Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI., ''Can we estimate the accuracy of ADME-Tox predictions?,'' [http://dx.doi.org/10.1016/j.drudis.2006.06.013 Drug Discov Today]. 2006 Aug;11(15-1615—16):700-7, [http://www.vcclab.org/~itetko/DDT.pdf pre-print].
* Tu B, Weissman J (2004). "Oxidative protein folding in eukaryotes: mechanisms and consequences". J Cell Biol 164 (3): 341-6. PMID 14757749.
* Vertuani S, Angusti A, Manfredini S (2004). "The antioxidants and pro-antioxidants network: an overview". Curr Pharm Des 10 (14): 1677-94. PMID 15134565.
== Spoljašnje veze ==
* https://web.archive.org/web/20070304050519/http://vam.anest.ufl.edu/demos/onecompbolus.html
* http://www.biokinetica.pl/en.html{{Мртва веза|date=09. 2018. |bot=InternetArchiveBot |fix-attempted=yes }}
* http://cti.itc.virginia.edu/~cmg/Demo/scriptFrame.html{{Мртва веза|date=08. 2018. |bot=InternetArchiveBot |fix-attempted=yes }}
* http://www.staff.uni-giessen.de/~gi38/publica/pharma/pharma.pdf
 
1.506.851

измена